ENERGESIS PHARMACEUTICALS INC

Boston, MA · Biotech · Private

Small-molecule therapeutics that activate brown adipocyte differentiation and thermogenesis via UCP1 pathway to treat obesity and metabolic disease

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · energesispharma.com

Sector: Biotech
Headquarters: Boston, MA
Total capital: $11.8M

Federal grants: $10.9M; 11 awards · 2015–2022; Rank in peer group#158 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $849K; 1 award · Defense; Rank in Biotech#199 of 4373
Granted patents: 4; 18 pending · first 2016; Rank in peer group#85 of 514

Capital timeline

Latest events

Jul 2022Federal grantHealth and Human S · Phase II · In Vivo Proof of Concept and Target Identification Using Small Molecule Stimulators of Brown Adipogenesis$970K
Aug 2021Federal grantHealth and Human S · Phase II · In Vivo Proof of Concept and Target Identification Using Small Molecule Stimulators of Brown Adipogenesis$2M
Jul 2021Federal grantHealth and Human S · Phase II · In Vivo Proof of Concept and Target Identification Using Small Molecule Stimulators of Brown Adipogenesis$1M
Jul 2020Federal grantHealth and Human S · Phase I · Development of Novel Brown Adipocyte Recruiters for the Treatment of Obesity$295K
Jun 2020Federal grantHealth and Human S · Phase I · Development of Novel Brown Adipocyte Recruiters for the Treatment of Obesity$295K
Jul 2018Federal grantHealth and Human S · Phase II · Optimization and Pre-Clinical Studies of a Protein Therapeutic for Recruiting Brown Adipocytes$982K
Sep 2017Federal grantHealth and Human S · Phase II · Optimization and Pre-Clinical Studies of a Protein Therapeutic for Recruiting Brown Adipocytes$794K

Show 5 earlier federal awards

Jun 2017Federal grantHealth and Human S · Phase II · Establishing In Vivo Proof of Concept of Brown Adipogenesis Using Approved Drugs$969K
Jun 2016Federal grantHealth and Human S · Phase II · Establishing In Vivo Proof of Concept of Brown Adipogenesis Using Approved Drugs$1.8M
Jun 2016Federal grantHealth and Human S · Phase II · Establishing In Vivo Proof of Concept of Brown Adipogenesis Using Approved Drugs$812K
Jul 2015Federal grantDefense · Phase II · Pre-Clinical Optimization of Human Brown Adipocyte Cell Therapy$999K
Oct 2011Federal contractDefense · STTR Phase 1 A11A-034-0222-1$849K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#158 · top 31%
Granted patents#85 · top 17%
Linked publications#61 · top 12%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 4 granted of 22

Nov 21, 2024PendingMethods And Compositions For Inducing Differentiation Of Human Brown Adipocyte ProgenitorsUSPTOApplication 18793859
Oct 17, 2024PendingBrown Adipocyte Progenitors In Human Skeletal MuscleUSPTOApplication 18760331
Jul 18, 2024PendingMethods And Compositions For Inducing Brown AdipogenesisUSPTOApplication 18561769

Show all 22 patent records

Methods And Compositions For Inducing Differentiation Of Human Brown Adipocyte ProgenitorsNov 21, 2024 · Application 18793859Pending
Brown Adipocyte Progenitors In Human Skeletal MuscleOct 17, 2024 · Application 18760331Pending
Methods And Compositions For Inducing Brown AdipogenesisJul 18, 2024 · Application 18561769Pending
Brown Adipocyte Progenitors in Human Skeletal MuscleJul 2, 2024 · US 12,025,612Granted
Analogs Of Human Fibroblast Growth FactorsSep 28, 2023 · Application 18021561Pending
Methods And Compositions For Inducing Brown AdipogenesisJun 22, 2023 · Application 17924694Pending
Methods And Compositions For Inducing Differentiation Of Human Brown Adipocyte ProgenitorsOct 20, 2022 · Application 17853992Pending
Methods and Compositions for Inducing Differentiation of Human Brown Adipocyte ProgenitorsAug 23, 2022 · US 11,419,916Granted
Brown Adipocyte Progenitors In Human Skeletal MuscleJul 21, 2022 · Application 17715082Pending
Brown Adipocyte Progenitors in Human Skeletal MuscleApr 12, 2022 · US 11,299,710Granted
Brown Adipocyte Progenitors in Human Skeletal MuscleOct 20, 2016 · Application 15198361Pending
Brown Adipocyte Progenitors in Human Skeletal MuscleAug 9, 2016 · US 9,410,945Granted
Brown Adipocyte Progenitors In Human Skeletal MuscleApplication PCTUS2012064366Pending
Methods And Compositions For Inducing Brown AdipogenesisApplication PCTUS2022030299Pending
Analogs Of Human Fibroblast Growth FactorsApplication PCTUS2021046602Pending
Methods And Compositions For Inducing Brown AdipogenesisApplication 63191271Pending
Methods And Compositions For Inducing Brown AdipogenesisApplication PCTUS2021031776Pending
Analogs of Human Fibroblast Growth FactorsApplication 63067675Pending
Methods and Compositions for Inducing Brown AdipogenesisApplication 63022640Pending
Methods And Compositions For Inducing Differentiation Of Human Brown Adipocyte ProgenitorsApplication PCTUS2015017392Pending
Compositions inducing differentiation of human brown adipocyte progenitorsApplication 61966496Pending
Brown Adipocyte Progenitors In Human Skeletal MuscleApplication PCTUS2012064389Pending

Recent research by its founders

Clinical Outcome after Cervical Arthroplasty Using the Novel One-Piece Viscoelastic Freedom Prosthesis20141 cites
Recruitment of Brown Adipose Tissue as a Therapy for Obesity-Associated Diseases201270 cites
Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP2010353 cites

NOMOCAN PHARMACEUTICALS LLCSimilar federal contract value in Biotech · $854K in contracts
Nanoscience Solutions, LLCSimilar federal contract value in Biotech · $849K in contracts
INTRA-CELLULAR THERAPIES, INC.Similar federal contract value in Biotech · $849K in contracts
SECOND GENOME, INC.Similar federal contract value in Biotech · $834K in contracts
Planet Biotechnology IncorporatedSimilar federal contract value in Biotech · $828K in contracts
SUJANA BIOTECH, LLCSimilar federal contract value in Biotech · $783K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.